top of page

US Loses Measles Elimination Status: What PAHO’s Ruling Means for America

2 minutes ago
19 min read

Introduction


The United States has lost its measles elimination status after the Pan American Health Organization (PAHO) determined that endemic transmission had returned. In a letter dated November 13, 2026, PAHO Director Jarbas Barbosa informed U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. that a continuous chain of measles transmission had persisted for more than 12 months. PAHO publicly announced the decision on November 17.


The determination ends a public-health designation the United States had maintained since 2000. It does not mean measles had disappeared from the country during those years. Rather, the United States had previously prevented imported infections from establishing sustained domestic transmission.


The immediate epidemiological picture is serious. According to the Centers for Disease Control and Prevention (CDC), the United States recorded 5,412 confirmed measles cases in 2026 as of November 12, more than twice the total reported for all of 2025. Declining vaccination coverage and prolonged outbreaks have weakened the population protection that supported elimination for more than two decades.


PAHO’s decision also raises institutional and legal questions. Its verification system operates through international public-health cooperation, while vaccination requirements, disease-control measures, and much of the outbreak response remain under American domestic authority. The consequences extend beyond the loss of a designation, but they should not be confused with a judicial finding, an international sanction, or an automatic change in U.S. law.


1. What Measles Elimination Status Means for America


Measles elimination is a recognized epidemiological achievement. A country qualifies when endemic transmission has been interrupted, supported by evidence from surveillance, laboratory testing, and outbreak investigations. The designation concerns sustained circulation of the virus within a defined geographical area.


The United States announced the elimination of endemic measles transmission in 2000, following decades of vaccination programs and improvements in disease surveillance. At the regional level, the Americas became the first WHO region verified as having eliminated endemic measles in 2016.


Those achievements depended on continued protection. Measles remained capable of entering the United States through international travel, and outbreaks could still occur among susceptible populations. The essential question was whether public-health authorities could identify and interrupt those outbreaks before transmission became established again.


1.1 Elimination, Eradication, and Endemic Transmission


Elimination and eradication have different meanings in infectious-disease control. Elimination refers to the interruption of endemic transmission within a particular geographical area. Eradication requires the permanent reduction of naturally occurring disease incidence to zero worldwide.


Measles has not been eradicated globally. Consequently, countries that eliminate endemic transmission remain exposed to imported infections. International travel can introduce the virus into communities where vaccination coverage is insufficient to prevent further spread.


An imported case does not, by itself, end elimination status. Nor does every outbreak establish endemic transmission. PAHO’s regional verification system treats uninterrupted transmission lasting at least 12 months as evidence that endemic circulation has been re-established.


Establishing such continuity requires more than counting cases. Epidemiologists examine the timing and geographical distribution of infections, exposure histories, connections between outbreaks, and laboratory evidence. Genetic information about circulating viruses can help investigators assess whether cases belong to continuing transmission chains or reflect separate introductions.


1.2 What the Loss Changes for Americans


The loss of elimination status changes the international classification of measles transmission in the United States. PAHO now regards the country as having re-established endemic measles, rather than merely experiencing outbreaks following imported infections.


For residents, the practical concern is increased exposure where the virus continues to circulate. Infants, susceptible children, and people who cannot receive certain vaccines may depend heavily on protection provided by vaccinated individuals around them. Health facilities, schools, and local authorities must respond to the circumstances of transmission in their communities.


The decision does not independently alter school-entry vaccination laws, create a nationwide vaccine mandate, or authorize PAHO to administer American health services. Those matters remain governed by the applicable constitutional, federal, state, and local legal arrangements. The distinction between an international institutional determination and its domestic effects reflects the broader relationship between international law and municipal law.


The designation nonetheless carries practical and reputational consequences. It signals that previous levels of disease control have not been maintained and establishes a formal basis for renewed regional scrutiny. Restoring the designation will require epidemiological progress that can be demonstrated to independent reviewers.


2. Why PAHO Revoked the U.S. Designation in 2026


PAHO withdrew the U.S. designation because its regional commission concluded that a single measles transmission chain beginning on January 20, 2025, had persisted for more than a year. The finding satisfied the regional criterion for re-established endemic transmission.


The decision followed a formal review of information submitted by American health authorities. It was not a conclusion reached solely from the cumulative number of measles cases. The commission assessed evidence of continuity, including epidemiological and laboratory information, within PAHO’s established verification process.


The institutional sequence is significant. An independent regional commission evaluated the evidence and recommended the change in classification. PAHO’s director accepted the recommendation and communicated the outcome to the U.S. government. The resulting decision is authoritative within the regional verification system, although it is not a judgment by an international court.


2.1 The Transmission Chain Beginning in January 2025


The relevant transmission chain began on January 20, 2025, during the emergence of a major measles outbreak in West Texas. Subsequent outbreaks occurred in several parts of the United States, placing sustained demands on state and local public-health agencies.


Early investigations in Texas documented infections, hospitalizations, and deaths among affected communities. CDC assistance supported epidemiological investigations and laboratory work, while state authorities carried out vaccination activities and measures intended to interrupt exposure.


PAHO identified January 20, 2026, as the point at which the original transmission chain reached the 12-month threshold. The eventual November decision was made after that threshold had already been crossed. The interval reflected the timing of the regional commission’s review rather than a different biological definition of endemic transmission.


The commission’s conclusion should be understood precisely. It found sufficient evidence that transmission associated with the relevant chain had continued over the required period. That finding does not establish that every outbreak reported throughout the United States belonged to the same chain or that measles circulated continuously in every state.


2.2 How PAHO Reached Its November Decision


PAHO established the Measles and Rubella Elimination Regional Monitoring and Re-Verification Commission in 2019 to monitor whether countries maintained elimination and to assess applications for renewed verification after setbacks.


The commission works with national sustainability bodies and health authorities. Its assessments depend on country reports, surveillance results, laboratory findings, and evidence of the measures taken to prevent or interrupt endemic transmission.


During its November 10–13, 2026 meeting in Washington, D.C., the commission reviewed the U.S. report and held discussions with members of the national sustainability commission and American health authorities. It concluded that the evidence demonstrated more than 12 months of sustained measles transmission.


Barbosa’s November 13 letter formally conveyed the outcome to Kennedy. The letter acknowledged American efforts involving surveillance, case detection, targeted vaccination, and coordination across the public-health system. It nevertheless classified the United States as endemic for measles and called for intensified action.


The decision was limited to measles. PAHO expressly stated that U.S. elimination status for rubella and congenital rubella syndrome remained unchanged. On November 17, the organization publicly confirmed that Bolivia and Mexico had also lost measles elimination verification following their respective assessments.


3. The U.S. Measles Resurgence in 2025–2026


The return of endemic transmission followed a sharp increase in reported measles infections. The CDC recorded 2,289 confirmed cases during 2025, compared with 285 in 2024. By November 12, 2026, the national count had reached 5,412.


These figures establish a substantial deterioration in disease control, although case totals alone cannot demonstrate the continuity required by PAHO’s verification framework. A country can experience numerous imported cases without establishing endemic transmission, just as one persistent chain may be epidemiologically decisive.


The American resurgence is associated with gaps in population immunity and the virus’s exceptional transmissibility. Measles can spread through the air, including in shared indoor environments, and susceptible individuals may become infected after exposure to an infectious person.


3.1 Measles Cases in 2026 and the National Outbreak


The CDC’s November 13 surveillance update reported 5,412 confirmed cases for 2026, based on information available through November 12. Of these, 5,394 were reported by 47 jurisdictions, while 18 involved international visitors to the United States.


The 47 reporting jurisdictions included the District of Columbia. The CDC also counted New York City and New York State as separate reporting jurisdictions. Consequently, the total should not be interpreted as representing 47 individual states.


Outbreak-associated transmission accounted for most reported infections. The CDC identified 43 new outbreaks during 2026 and classified 5,216 cases, approximately 96% of the national total, as associated with outbreaks that began in either 2025 or 2026.


Mortality figures require particular care because national and state reporting did not use identical classifications or reporting schedules. The CDC’s provisional national dashboard listed six measles deaths in 2026 as of November 12. On November 13, Pennsylvania reported seven measles-associated deaths during the year, and Wisconsin reported two. New York had separately reported a pediatric measles-associated death on November 2, bringing those state-reported totals to ten.


The higher combined state figure does not mean that the CDC’s six deaths were necessarily erroneous. Federal and state authorities were using different reporting processes, and the CDC stated that its national count remained subject to review. It was also working with the Council of State and Territorial Epidemiologists on more consistent classification of deaths attributable to measles.


3.2 Vaccination Gaps and the Return of Endemic Measles


Vaccination coverage is central to the difference between an imported infection that produces a limited outbreak and one that generates sustained transmission. Measles is highly contagious, making communities particularly vulnerable when substantial numbers of susceptible individuals are concentrated together.


The CDC estimates that one dose of measles-containing vaccine is approximately 93% effective at preventing measles, while two doses provide approximately 97% protection. Its routine childhood recommendation is two doses of the measles, mumps, and rubella (MMR) vaccine, generally administered at 12–15 months and again at four to six years of age.


National kindergarten MMR coverage declined from 95.2% in the 2019–2020 school year to 92.4% in 2025–2026. The CDC estimated that approximately 280,000 kindergarteners were at risk during the latter school year. That description should not be interpreted as a claim that every child in the estimate had exactly the same vaccination history.


National averages also conceal important local differences. Communities may experience substantial transmission even when statewide coverage appears relatively high. The concentration of susceptible individuals in schools, households, religious communities, or other social networks can permit outbreaks to continue.


Vaccination-status data require similar precision. Surveillance categories sometimes combine confirmed unvaccinated individuals with people whose vaccination history is unknown. A combined category provides evidence about the characteristics of reported cases but cannot establish that every person within it was unvaccinated.


Declining coverage reflects several possible contributing conditions, including disruptions to routine health services, access barriers, and vaccine hesitancy. The relative importance of those factors differs among communities. Their contribution to the national resurgence should not be reduced to a single political explanation without evidence capable of establishing that causal relationship.


3.3 Children, Vulnerable Groups, and Measles Complications


Measles is sometimes described as an ordinary childhood infection, but its complications can be severe. Pneumonia, dehydration, encephalitis, and death are recognized outcomes. Infection can also impair immune protection against other pathogens, while rare neurological complications may emerge years after the initial illness.


Young children face particular risks, especially infants who have not yet reached the usual age for their first routine MMR dose. Pregnant individuals and people with weakened immune systems may also experience serious consequences. Some cannot receive a live-attenuated vaccine because of medical contraindications.


The outbreak has demonstrated that these risks are not merely theoretical. State health departments have reported pediatric deaths and serious illness during 2026. Their responses have included epidemiological investigations, vaccination clinics, clinical guidance, and measures designed to limit further exposure.


International human-rights law provides a broader framework for understanding epidemic prevention. Article 12(2)(c) of the International Covenant on Economic, Social and Cultural Rights addresses the prevention, treatment, and control of epidemic and endemic diseases as part of the right to health.


The United States signed the Covenant in 1977 but has not ratified it. Its Article 12 obligations consequently cannot be presented as binding U.S. treaty commitments arising from ratification. The provision remains relevant to international public-health principles, although the legal consequences of America’s measles resurgence must be assessed under the instruments and domestic rules actually applicable to the country.


4. Robert F. Kennedy Jr. and Federal Health Policy


Robert F. Kennedy Jr. became a central figure in the public response to the loss of U.S. measles elimination status because he leads the Department of Health and Human Services. His earlier public criticism of aspects of vaccination policy also made the resurgence politically contentious.


The chronology imposes an important limit on assigning responsibility. The transmission chain identified by PAHO began on January 20, 2025, before Kennedy assumed office. Its origins cannot reasonably be attributed to decisions he subsequently made as health secretary.


That does not remove federal policy from scrutiny. By November 2026, the administration had responsibility for major elements of national public-health coordination, federal surveillance support, vaccine guidance, laboratory capacity, and assistance to affected jurisdictions. The relevant assessment concerns how those responsibilities were exercised as transmission continued.


In its November 17 joint statement, the CDC reported approximately $100 million in additional funding provided nationwide since August 2026 for prevention and response to measles and other vaccine-preventable diseases. The announced support included $50.2 million through a vaccine-preventable disease cooperative agreement and $49.8 million through an epidemiology and laboratory-capacity agreement. The funding was intended to support activities extending through much of 2027.


The CDC also reported deploying epidemiological assistance teams at the request of state and local authorities. Its statement identified jurisdictions that had received assistance and emphasized laboratory testing, outbreak investigations, vaccination access, and data sharing. Kennedy and CDC Director Erica Schwartz continued to recommend MMR vaccination as the principal means of preventing measles.


The American Academy of Pediatrics and the Infectious Diseases Society of America have publicly criticized vaccination-policy decisions taken under Kennedy’s leadership. Both organizations expressed concern that changes to established federal recommendations and advisory processes could undermine confidence in immunization and weaken disease prevention. Their objections reflect documented positions on federal policy, not proof that a particular decision or statement caused a specific measles outbreak.


The administration has emphasized that declining vaccination coverage preceded its tenure and that measles resurgence is not confined to the United States. Both observations are compatible with the epidemiological record. Their existence does not resolve whether the federal response has been adequate, which requires evidence about vaccination uptake, transmission interruption, resource deployment, and the performance of surveillance systems.


The policy question is consequently more precise than a dispute over one official’s personal views. It concerns whether national leadership can support consistent vaccination recommendations, maintain effective cooperation with state authorities, and direct resources toward communities experiencing sustained transmission. The effectiveness of the announced measures will depend on results rather than the amounts allocated or the political claims made about them.


5. PAHO's Authority and the International Legal Consequences


PAHO’s decision is internationally significant, but its legal character must be understood within the organization’s mandate. The withdrawal of elimination verification is a determination concerning the epidemiological status of the United States under a regional monitoring system.


It is not a declaration by an international court that the United States has committed an internationally wrongful act. Nor does it independently impose damages, financial penalties, compulsory vaccination measures, or restrictions on international travel.


The international legal questions arise principally from PAHO’s institutional position, the relationship between the United States and WHO, and the separate rules governing international notification and cooperation concerning public-health events.


5.1 PAHO, WHO, and American Institutional Membership


PAHO originated in 1902 and developed into the specialized health organization of the inter-American system. It also serves as the WHO Regional Office for the Americas under institutional arrangements approved in 1949.


These functions coexist without eliminating PAHO’s separate legal personality and institutional autonomy. The organization has its own governing arrangements, membership, and regional responsibilities. The legal powers of international organizations depend on their constituent instruments and assigned functions, rather than on a general authority equivalent to state sovereignty.


That distinction reflects the broader principle that international organizations possess distinct legal personality, with capacities and responsibilities determined by their respective mandates. PAHO’s authority to administer regional elimination verification should be assessed within that institutional structure.


The United States remains listed among PAHO’s member states. Its relationship with PAHO must be distinguished from the Trump administration’s decision to withdraw from WHO. In January 2026, the U.S. government announced that it had completed its WHO withdrawal following the notice initiated in January 2025.


The international legal position is more complicated than that executive announcement alone suggests. Section 290c of Title 22 of the United States Code reserves a U.S. right to withdraw from WHO on one year’s notice, subject to full payment of specified financial obligations. WHO’s Executive Board documentation, including document EB158/45, examined questions concerning the interpretation of those conditions and their fulfillment.


On May 22, 2026, the World Health Assembly adopted resolution WHA79.2, which identified the United States among countries with significant outstanding assessed contributions. The resolution demonstrates that financial obligations remained an active institutional issue after Washington had announced completion of its withdrawal. It does not, by itself, resolve every question concerning the withdrawal’s legal effectiveness.


The measles decision is not dependent on settling that dispute. PAHO’s separate regional verification arrangements continued to operate, and American health authorities participated in the November assessment. The relevant institutional question is whether the country maintained the epidemiological conditions required for measles elimination, not whether withdrawal from WHO deprived PAHO of its regional verification function.


5.2 The International Health Regulations and U.S. Duties


The International Health Regulations (2005) establish a legally binding framework for participating states to assess, report, and respond to public-health events with potential international consequences. Their provisions address surveillance capacities, national focal points, notification, verification, and cooperation with WHO.


Article 5 and Annex 1 concern surveillance and response capacities. Article 6 requires participating states to assess events under the decision instrument in Annex 2 and notify WHO of qualifying events. Subsequent provisions address additional information-sharing, consultation, and verification procedures.


Measles is not listed among the diseases requiring automatic notification in every case under Annex 2. The legal question is whether the circumstances of a particular event satisfy the decision instrument, including its assessment of public-health seriousness, unusual characteristics, risk of international spread, and potential interference with international travel or trade.


The distinction between routine disease surveillance and an internationally notifiable event is substantive. A measles outbreak does not automatically become a public health emergency of international concern, and PAHO’s withdrawal of elimination verification is not equivalent to such a declaration. WHO verification procedures under Articles 9 and 10 operate on a different legal basis, illustrated by their application to other reported infectious-disease events, including the WHO verification procedures concerning the suspected Irkutsk plague case.


The applicable version of the Regulations must also be specified. WHO’s June 2026 consolidated participation record identifies the United States as having accepted the 2005 Regulations, with a reservation concerning federalism, and as subject to the 2014 and 2022 amendments. It records the United States’ rejection of the 2024 amendments, formally announced by the Departments of State and Health and Human Services in July 2025.


That rejection did not constitute rejection of the entire IHR framework. WHO expressly recognized that earlier versions remained applicable to states rejecting the 2024 amendments. The U.S. federalism reservation also acknowledges that implementation of certain national capacities may occur through federal or state governments, consistent with the country’s constitutional arrangements.


The relationship between WHO withdrawal and continued IHR participation requires separate legal analysis. Article 64 provides mechanisms through which states outside WHO membership may participate in the Regulations and, under its specified conditions, withdraw from that participation. A claimed withdrawal from WHO membership should not automatically be treated as an independently established withdrawal from every regulatory arrangement administered through WHO.


No breach of the IHR follows merely from losing measles elimination status. A legal finding of noncompliance would require identification of an applicable obligation, conduct inconsistent with that obligation, and the circumstances governing its application. The epidemiological reversal is serious evidence of a public-health problem, but it is not itself a legal judgment establishing treaty responsibility.


6. The United States in the Americas' Measles Reversal


The United States is not the only country in the Americas to experience the return of endemic measles transmission. The regional elimination achievement of 2016 was subsequently challenged by outbreaks in several countries, demonstrating how difficult it is to sustain population protection when the virus continues circulating elsewhere.


Venezuela and Brazil re-established endemic transmission in 2018 and 2019, respectively. Following intensified vaccination, surveillance, and outbreak-control efforts, Venezuela regained its measles-free status in 2023 and Brazil in 2024.


These recoveries allowed the Americas to regain regional elimination verification in 2024. That achievement proved temporary. Canada’s re-establishment of endemic transmission led to the loss of regional measles elimination status in November 2025.


The November 2026 decisions concerning the United States, Mexico, and Bolivia represented a further deterioration. PAHO identified sustained transmission chains beginning on January 20, 2025, in the United States; February 1, 2025, in Mexico; and April 16, 2025, in Bolivia. The determinations were based on the circumstances of each country rather than an assumption that all outbreaks formed a single cross-border transmission chain.


Regional surveillance also reveals the scale of the problem. PAHO reported 58,213 confirmed measles cases and 82 deaths across the Americas as of November 13, 2026. Those figures reflected a major resurgence affecting countries with different health systems, vaccination patterns, and outbreak histories.


Cross-border movement gives the situation a diplomatic dimension. A country that interrupts endemic transmission remains vulnerable to new introductions while measles circulates elsewhere. Effective control depends on national vaccination programs, rapid identification of infections, laboratory cooperation, and timely exchange of information between public-health authorities.


Cooperation does not require every state to adopt identical domestic health measures. National legal systems allocate powers differently, and local outbreak conditions vary. The shared regional objective is to prevent imported infections from developing into sustained transmission.


The Americas’ earlier recoveries demonstrate that the loss of verification need not be permanent. They also show that achieving elimination once does not secure it indefinitely. Regional progress depends on maintaining protective conditions after the immediate emergency has receded.


7. How the United States Can Regain Elimination Status


Regaining measles elimination status requires the United States to interrupt endemic transmission and demonstrate that the interruption is sustained. The objective is epidemiological, but meeting it depends on coordinated administrative and institutional action.


A decline in reported cases would be encouraging, yet it would not alone establish elimination. Surveillance must remain capable of detecting cases, investigating suspected transmission chains, and distinguishing imported infections from continuing domestic circulation.


PAHO’s regional commission must ultimately be satisfied that the country meets the verification criteria. Political announcements or the completion of a specified number of vaccination campaigns cannot substitute for the required evidence.


7.1 Breaking Transmission and Restoring Community Protection


The most direct means of preventing measles transmission is maintaining sufficiently high vaccination coverage. Because the virus spreads efficiently, national averages offer limited reassurance where communities contain concentrated pockets of susceptible individuals.


Targeted vaccination programs can address those gaps, particularly where outbreaks reveal populations with limited access to routine services. Health authorities also need accurate vaccination records, accessible clinical advice, and reliable communication about recommended doses.


Rapid case detection remains essential. Investigations must identify exposures, trace contacts where appropriate, and guide measures intended to prevent further infection. Laboratories contribute by confirming cases and supporting assessment of transmission patterns.


The CDC’s November 2026 response emphasized the responsibilities of state, local, tribal, and territorial health departments alongside federal assistance. Such coordination is particularly important in a federal system because many practical disease-control powers are exercised below the national level.


Public confidence and access to vaccination affect whether technical recommendations translate into protection. Communities may face different obstacles, including limited healthcare availability or distrust of institutions. Effective measures require responses suited to those conditions while remaining consistent with applicable domestic law and established medical evidence.


7.2 Corrective Action Plans and Formal Re-Verification


PAHO’s November 13 letter called for the United States to submit a corrective action plan setting out the measures intended to restore elimination. The requirement belongs to the regional verification process and should not be confused with a sanction imposed under an international judgment.


The plan must address the conditions that permitted sustained transmission. Relevant measures include improved vaccination coverage, stronger surveillance, rapid outbreak response, and the capacity to document whether endemic transmission has ended.


Re-verification requires evidence that endemic transmission has been interrupted for at least 12 consecutive months. Epidemiological and laboratory records must support that conclusion. A country cannot recover its designation merely by reaching the anniversary of an announced policy initiative.


The regional commission assesses the evidence through its established procedures and advises PAHO on the country’s status. The date of any future review may depend on the submission of sufficient national information and the commission’s meeting arrangements. No reliable basis exists for promising the United States a particular date of reinstatement.


PAHO’s corrective procedures illustrate how international public-health institutions can shape national conduct through technical standards and verification rather than compulsory domestic legislation. Such arrangements have features associated with non-binding international standards and institutional guidance, although their legal character must be distinguished from the binding obligations contained in separate instruments such as the IHR.


The practical test will be whether the United States can maintain the necessary protection after current outbreaks subside. Re-establishing elimination requires sustained public-health performance, independently assessed, rather than a temporary reduction in disease incidence.


Conclusion


The United States lost measles elimination status because PAHO determined that a transmission chain beginning in January 2025 had continued for more than 12 months. The November 2026 decision reverses an achievement maintained since 2000 and places the country among those in the Americas where endemic measles transmission has returned.


The public-health consequences are more immediate than the institutional designation. Thousands of confirmed infections, declining kindergarten vaccination coverage, and reported deaths demonstrate that susceptible populations remain exposed to a preventable disease capable of causing serious illness.


Internationally, PAHO’s determination establishes a new epidemiological classification and initiates the process of corrective action and eventual re-verification. It does not automatically change domestic vaccination laws or establish a breach of an international treaty. The separate questions concerning U.S. participation in WHO and the International Health Regulations require analysis under their own legal frameworks.


Restoration will depend on whether American authorities can interrupt sustained transmission, close gaps in protection, and produce credible evidence of lasting control. The distinction between losing a designation and losing the conditions that justified it is fundamental: renewed verification will follow only when those conditions have been restored.


References


Centers for Disease Control and Prevention (2026a) ‘Joint Statement: Loss of U.S. Measles Elimination Status’, 17 November [online]. Available at: https://www.cdc.gov/media/releases/2026/loss-of-usmeasles-elimination-status.html (Accessed: 18 November 2026).


Centers for Disease Control and Prevention (2026b) ‘Measles Cases and Outbreaks’, updated 13 November [online]. Available at: https://www.cdc.gov/measles/data-research/index.html (Accessed: 18 November 2026).


Centers for Disease Control and Prevention (2026c) ‘Measles Vaccine Recommendations’, 3 March [online]. Available at: https://www.cdc.gov/measles/hcp/vaccine-considerations/ (Accessed: 18 November 2026).


Infectious Diseases Society of America (2025) ‘Leading Medical Professional Societies, Patient Sue HHS, Robert F. Kennedy, Jr. for Unlawful, Unilateral Vaccine Changes’, 7 July [online]. Available at: https://www.idsociety.org/news--publications-new/articles/2025/leading-medical-professional-societies-patient-sue-hhs-robert-f.-kennedy-jr.--for-unlawful-unilateral-vaccine-changes (Accessed: 18 November 2026).


International Covenant on Economic, Social and Cultural Rights (1966) Adopted 16 December 1966; entered into force 3 January 1976. 993 UNTS 3, No. 14531.

New York State Department of Health (2026) ‘Joint Statement From New York State Department of Health and Lewis County Public Health on Pediatric Measles-Associated Death in Lewis County’, 2 November [online]. Available at: https://press.health.ny.gov/node/74 (Accessed: 18 November 2026).


Pan American Health Organization (n.d.) ‘About the Pan American Health Organization’ [online]. Available at: https://www.paho.org/en/who-we-are (Accessed: 18 November 2026).


Pan American Health Organization (n.d.) ‘Measles and Rubella Elimination Regional Monitoring and Re-Verification Commission’ [online]. Available at: https://www.paho.org/en/measles-rubella-elimination-regional-monitoring-re-verification-commission (Accessed: 18 November 2026).


Pan American Health Organization (n.d.) ‘Member States of the Pan American Health Organization’ [online]. Available at: https://www.paho.org/en/planning-finance-and-accountability/member-states-pan-american-health-organization (Accessed: 18 November 2026).


Pan American Health Organization (2026a) Letter from Director Jarbas Barbosa da Silva Jr. to Robert F. Kennedy Jr., U.S. Secretary of Health and Human Services, CIM-150-26, 13 November [online]. Available at: https://www.cdc.gov/media/media/files/2026/11/CIM-2026-0059.pdf (Accessed: 18 November 2026).


Pan American Health Organization (2026b) ‘Measles in the Americas: Questions and Answers – Technical Reference for Journalists and the Public’, 17 November [online]. Available at: https://www.paho.org/en/news/17-11-2026-measles-americas-questions-and-answers-technical-reference-journalists-and-public (Accessed: 18 November 2026).


Pan American Health Organization (2026c) ‘PAHO Urges Countries to Step Up Efforts to Stop Measles Outbreaks and Move Towards Elimination in the Americas’, 17 November [online]. Available at: https://www.paho.org/en/news/17-11-2026-paho-urges-countries-step-efforts-stop-measles-outbreaks-and-move-towards (Accessed: 18 November 2026).


Pennsylvania Department of Health (2026) ‘Pennsylvania Department of Health Confirms Seventh Measles-Associated Death, Provides Statewide Update on Measles Outbreak as Cases Reach 1,542 in 46 Counties’, 13 November [online]. Available at: https://www.pa.gov/agencies/health/newsroom/pa-department-of-health-confirms-seventh-measles-associated-deat (Accessed: 18 November 2026).


United Nations Treaty Collection (n.d.) ‘International Covenant on Economic, Social and Cultural Rights’, Chapter IV, No. 3, Multilateral Treaties Deposited with the Secretary-General [online]. Available at: https://treaties.un.org/doc/Publication/MTDSG/Volume%20I/Chapter%20IV/iv-3.en.pdf (Accessed: 18 November 2026).


United States Code (2026) 22 U.S.C. § 290c, ‘Withdrawal from Organization on One-Year Notice’ [online]. Available at: https://uscode.house.gov/us/usc/119-142/t22/s290c/ (Accessed: 18 November 2026).


United States Department of Health and Human Services (2025) ‘HHS & State Department: The United States Rejects Amendments to International Health Regulations’, 18 July [online]. Available at: https://www.hhs.gov/press-room/state-department-hhs-rejects-amendments-to-international-health-regulations.html (Accessed: 18 November 2026).


United States Department of Health and Human Services (2026) ‘Fact Sheet: U.S. Withdrawal from the World Health Organization’, 22 January [online]. Available at: https://www.hhs.gov/press-room/fact-sheet-us-withdrawal-from-the-world-health-organization.html (Accessed: 18 November 2026).


Wang, D. et al. (2026) ‘Characteristics of Patients Hospitalized with Measles During an Outbreak — West Texas, January–March 2025’, Morbidity and Mortality Weekly Report, 75(20), pp. 252–257. Available at: https://www.cdc.gov/mmwr/volumes/75/wr/mm7520a1.htm (Accessed: 18 November 2026).


Wisconsin Department of Health Services (2026) ‘Wisconsin DHS Reports Second Death Connected to the Ongoing Measles Outbreak’, 13 November [online]. Available at: https://www.dhs.wisconsin.gov/news/releases/111326.htm (Accessed: 18 November 2026).


World Health Assembly (2026) ‘Status of Collection of Assessed Contributions, Including Member States in Arrears in the Payment of Their Contributions to an Extent That Would Justify Invoking Article 7 of the Constitution’, Resolution WHA79.2, 22 May [online]. Available at: https://apps.who.int/gb/ebwha/pdf_files/WHA79/A79_R2-en.pdf (Accessed: 18 November 2026).


World Health Organization (2025) ‘Amended International Health Regulations Enter into Force’, 19 September [online]. Available at: https://www.who.int/news/item/19-09-2025-amended-international-health-regulations-enter-into-force (Accessed: 18 November 2026).


World Health Organization (2026a) Collaboration Within the United Nations System and With Other Intergovernmental Organizations: Communications of the United Nations Secretary-General as Depositary of the Constitution of the World Health Organization. Report by the Director-General, Executive Board, 158th session, document EB158/45, 20 January [online]. Available at: https://apps.who.int/gb/ebwha/pdf_files/EB158/B158_45-en.pdf (Accessed: 18 November 2026).


World Health Organization (2026b) International Health Regulations (2005): As Amended in 2014, 2022 and 2024. Consolidated text dated 19 June 2026. Geneva: World Health Organization [online]. Available at: https://apps.who.int/gb/bd/pdf_files/IHR_2014-2022-2024-en.pdf (Accessed: 18 November 2026).

SUPPORT DIPLOMACY & LAW

Was this article useful?

If our analysis helped you better understand an issue or supported your research, consider making a contribution. Your support helps fund independent research and keeps our international law publications freely accessible to everyone.

bottom of page